Stocktoria
Maze Therapeutics, Inc. MAZE
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2025-01-31
Chart by TradingView
2/9
Piotroski F — financial health
7.81
Altman Z″ — distress risk · safe
—
Dividend payout · no dividend
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2024 |
|---|---|---|
| Financials | ||
| Revenue | — | $167.5M |
| Operating income | -$142.9M | $57.6M |
| Net income | -$131.1M | $52.2M |
| Operating cash flow | -$111.9M | $76.0M |
| Free cash flow | -$112.7M | $74.8M |
| Total assets | $397.1M | $240.5M |
| Total liabilities | $42.2M | $43.6M |
| Shareholders' equity | $355.0M | -$311.2M |
| Ratios | ||
| Operating margin | — | 34.4% |
| Net margin | — | 31.2% |
| FCF margin | — | 44.7% |
| Return on assets | -33.0% | 21.7% |
| Return on equity | -36.9% | -16.8% |
| Current ratio | 15.50 | 9.76 |
Notable holders (13F)
| Investor | Shares | Value |
|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC | 15,800 | $471,630 |
Why these scores methodology →
Piotroski F-score: 2/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: 7.81 (safe)
- Working capital / assets 0.824
- Retained earnings / assets -1.233
- EBIT / assets -0.36
- Equity / liabilities 8.419
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0001842295 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.